about
Network medicine analysis of COPD multimorbiditiesNetwork medicine, multimorbidity and the lung in the elderlyPersonalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014The inflammasome pathway in stable COPD and acute exacerbationsSystemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect.Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.The microbiome in respiratory medicine: current challenges and future perspectives.An investigation of the resolution of inflammation (catabasis) in COPD.Systemic inflammation and comorbidities in chronic obstructive pulmonary disease.Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.Immune response in chronic obstructive pulmonary disease.Lessons from ECLIPSE: a review of COPD biomarkers.Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema.Biomarkers, the control panel and personalized COPD medicine.Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model.Population structure in copy number variation and SNPs in the CCL4L chemokine gene.ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression.Molecular and clinical diseasome of comorbidities in exacerbated COPD patients.The EASI model: A first integrative computational approximation to the natural history of COPDDevelopment of a new HLA-DRB real-time PCR typing method.A SNP in intron 1 of TSHR controls its thymic expression and susceptibility to Graves’ disease suggesting central tolerance failure in pathogenesis.Towards a global initiative for fibrosis treatment (GIFT).Lung function in early adulthood and health in later life: a transgenerational cohort analysis.COPD: algorithms and clinical management.Multi-level differential network analysis of COPD exacerbations.Precision medicine in airway diseases: moving to clinical practice.What does endotyping mean for treatment in chronic obstructive pulmonary disease?Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers.Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.Hospitalizations due to exacerbations of COPD: A big data perspective.From systems biology to P4 medicine: applications in respiratory medicine.Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.COPD beyond smoking: new paradigm, novel opportunities.The Changing Landscape of COPD.High resolution definition of HLA-DRB haplotypes by a simplified microsatellite typing technique.HLA-DQ2/DQ8 and HLA-DQB1*02 homozygosity typing by real-time polymerase chain reaction for the assessment of celiac disease genetic risk: evaluation of a Spanish celiac population.Network analysis: a way forward for understanding COPD multimorbidity.Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.Real-time PCR using fluorescent resonance emission transfer probes for HLA-B typing.Bone marrow characterization in COPD: a multi-level network analysis.
P50
Q21146673-23BC77B3-2129-4816-BA02-DF847089CA98Q27022209-5938E15E-4CE5-4C6F-AB02-C8E79252A9A4Q27027259-95F88C0A-77FF-415D-8DE5-0262927F06ACQ28598391-9C6AF4F3-8CBB-4F7C-99CC-71F2137EF8D6Q33617957-C6055A52-C796-497C-98A0-DFA87B39CC61Q33617957-D70BCD47-23E5-426F-8ED9-DF993E27B746Q33697574-1FD35D4F-E151-4D6B-BF7F-DD817CAAE06CQ36345295-80851CA8-A51C-44DA-9AE9-1B5D63906488Q36539037-D171292C-2350-404A-A792-467FF16C47E2Q38006928-FF477A84-84CE-43D8-9B6E-31862C3EE35EQ38009797-72C84892-C829-449E-B07D-B193D3476814Q38144104-10058BAF-2FA3-497A-B639-0BE89079D074Q38169066-8A076030-DB29-4B44-B113-CA03A5CBEF04Q38452733-70DBF1E5-EC77-4AAC-BDD9-7D54FC560EA2Q38546748-A07237A9-8FE4-4E00-A0C0-D45F23B838E7Q38733865-937ED81C-3D6E-45A0-85CA-6195B66A404CQ38951086-95068F30-5BB6-4436-8F9C-E4F40E3B56E7Q39733837-3B18D7C1-FBF6-445B-8283-EBECA789740DQ40650568-E5543F9D-4F80-49C4-95B8-DE16CF1A5D40Q42696087-60409D12-EAE0-4405-9349-9A18AB8ED823Q45202634-628A6A35-9EB6-4E8C-95E5-59E75A11FD90Q46090342-DBCF2E3D-BFF6-41CE-982F-EB270800EC09Q47152449-54068E14-A679-40F2-90E3-2DC3B9FB2B16Q47576663-A6754B8D-81D9-4C76-8D52-074A0D571260Q47621638-91C8D14C-75D9-4C21-AA9E-6F712126181CQ47735175-537A6D66-1700-4981-BC48-2AA5F70AEF73Q47738767-ECB12F68-842B-471F-8397-AF684AA65C21Q47782931-005837CA-D335-41A7-A873-07E15B69F30BQ47906245-29720275-AEC5-4C7C-BFC0-383363E3A135Q48013951-5A33843D-596B-4CD5-BEA6-1EDB0AF73FD5Q49343017-C251A0D8-6204-43E2-B597-A6A214BDF973Q50048603-43D178DB-3D73-4730-9CC7-737D44672D5FQ50440978-52BBC5C7-998C-484F-8FF9-725DC42FD2CAQ52678544-32B38FF8-F047-4145-9461-866C244EDDE6Q53821262-57DF22C0-9C98-46B2-B2BA-A04546A4751DQ53876788-540D1604-BE13-4B1C-9368-48939BA76226Q54184367-1954B316-D239-4CF6-A005-3E65BCA17DF9Q54281109-37D16F1D-6F5E-4DA8-82D8-8673A713390BQ54367442-7CABC4EF-F005-4CAD-9C26-610B41AA94CEQ54600238-DFFE8CF6-553A-462A-81B5-5945BCA36BAB
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rosa Faner
@ast
Rosa Faner
@en
Rosa Faner
@es
Rosa Faner
@fr
Rosa Faner
@nl
Rosa Faner
@sl
type
label
Rosa Faner
@ast
Rosa Faner
@en
Rosa Faner
@es
Rosa Faner
@fr
Rosa Faner
@nl
Rosa Faner
@sl
prefLabel
Rosa Faner
@ast
Rosa Faner
@en
Rosa Faner
@es
Rosa Faner
@fr
Rosa Faner
@nl
Rosa Faner
@sl
P106
P1153
6507910788
P21
P31
P496
0000-0002-8159-0115